Mechano-Signaling Aspects of Hepatocellular Carcinoma.

HCC is one of the leading causes of cancer related death worldwide and comprises about 90% of the cases of primary liver cancer. It is generally accompanied by chronic liver fibrosis characterised by deposition of collagen fibres, which, in turn, causes enhanced stiffness of the liver tissue. Changes of tissue stiffness give rise to alterations of signalling pathways that are associated to mechanical properties of the cells and the extracellular matrix, and that can be subsumed as "mechano-signaling pathways", like, e.g., the YAP/TAZ pathway, or the SRF pathway. Stiffness of the liver tissue modulates mechanical regulation of many genes involved in HCC progression. However, mechano-signaling is still rather underrepresented in our concepts of cancer in comparison to "classical" biochemical signalling pathways. This review aims to give an overview of various stiffness induced mechano-biological aspects of HCC.

Theranostic nanozyme: Silk fibroin based multifunctional nanocomposites to combat oxidative stress.

Multifunctional nanomaterials integrating therapeutic and imaging modalities in one platform have opened a new era in the present therapeutic strategies. In the present study, a multifunctional silk fibroin-based carrier has been designed for the delivery of antioxidant and imaging agents. One-step desolvation method was used to prepare sulforaphane (antioxidant drug) loaded silk fibroin nanoparticles (SFSNPs). These anionic SFSNPs were further coupled with cationic cerium oxide nanoparticles (CeNPs) and PEI passivated carbon dots (CDs) to form self-assembled CeNP-CD@SFSNPs nanocomposites. CDs were synthesized from mulberry leaves (Morus indica) as green source of carbon and bPEI as a passivating agent to get positively charged CDs. The CDs functioned as molecular probes by emitting green fluorescence while the presence of CeNPs augmented the antioxidant potential due to their unique redox property. Time-dependent in vitro release of sulforaphane was fast in acidic pH than under normal physiological conditions. Cytotoxicity studies were performed on L132 normal epithelial lung cell lines and A549 lung cancer cell lines to analyze the toxicity of the nanocomposites. Green fluorescence from the CDs facilitated in fluorescence microscopic imaging and cellular uptake studies. ROS scavenging capability was analyzed by exposing cells to H2O2 stress using flow cytometry and DCFH-DA staining. Overall, the synthesized CeNP-CD@SFSNPs nanocomposites efficiently reduced ROS levels by simultaneously enabling imaging of the cells. Thus, this CeNP-CD@SFSNPs nanocomposite could be a potential candidate for simultaneous imaging and drug delivery against oxidative stress.

Conventional and Nanotechnology Based Approaches to Combat Chronic Obstructive Pulmonary Disease: Implications for Chronic Airway Diseases.

Chronic obstructive pulmonary disease (COPD) is the most prevalent obstructive lung disease worldwide characterized by decline in lung function. It is associated with airway obstruction, oxidative stress, chronic inflammation, mucus hypersecretion, and enhanced autophagy and cellular senescence. Cigarette smoke being the major risk factor, other secondary risk factors such as the exposure to air pollutants, occupational exposure to gases and fumes in developing countries, also contribute to the pathogenesis of COPD. Conventional therapeutic strategies of COPD are based on anti-oxidant and anti-inflammatory drugs. However, traditional anti-oxidant pharmacological therapies are commonly used to alleviate the impact of COPD as they have many associated repercussions such as low diffusion rate and inappropriate drug pharmacokinetics. Recent advances in nanotechnology and stem cell research have shed new light on the current treatment of chronic airway disease. This review is focused on some of the anti-oxidant therapies currently used in the treatment and management of COPD with more emphasis on the recent advances in nanotechnology-based therapeutics including stem cell and gene therapy approaches for the treatment of chronic airway disease such as COPD and asthma.